Gan & Lee Pharmaceuticals (SHA:603087) expects its net profit attributable to shareholders in 2025 to jump between 79% and 95% year on year to 1.10 billion yuan and 1.20 billion yuan, according to a Shanghai bourse filing on Thursday.
The Chinese pharmaceutical company's attributable profit a year earlier was 614.7 million yuan or 1.04 yuan per share.
The company's shares slipped nearly 2% during the morning trade Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments